Company / Capital Expenditures
Traws Pharma, Inc. Capital Expenditures History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$14.0K
FY2024
5-year range
$14.0K / $55.0K
FY2020-FY2024
Trend
+0.0%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $15,000 to $14,000 over the past 3 years.
Based on SEC 10-K filings.
$14,000 in FY2024 with a 5-year CAGR of -23.9%.
Declined from $15,000 to $14,000 over the past 3 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -2.3%
- 5-Year CAGR
- -23.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -23.9%, indicating a declining trend.
- In FY2024, capital expenditures increased 0.0% year-over-year.
- Peak capital expenditures was recorded in FY2015.
Company context
Key Data Points
- Altman Z-Score -42.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $14.0K | +0.0% |
| FY2023 | $14.0K | - |
| FY2022 | - | - |
| FY2021 | $15.0K | -72.7% |
| FY2020 | $55.0K | +0.0% |
| FY2019 | $55.0K | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
| FY2015 | $228.0K | -18.3% |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026